Aldosterone blockade in chronic kidney disease

Seminars in Nephrology

Volumn 34, Issue 3, 2014, Pages 307-322

  Hirsch, Jamie S ^a   Drexler, Yelena ^a   Bomback, Andrew S ^a  

^a Department of Medicine Division of Nephrology Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Aldosterone; Chronic kidney disease; Proteinuria; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LOSARTAN; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; ALDOSTERONE; MINERALOCORTICOID ANTAGONIST;

ALPORT SYNDROME; ARTERY DILATATION; AUGMENTATION INDEX; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIETARY INTAKE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART RATE VARIABILITY; HOMEOSTASIS; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; LIPID PEROXIDATION; MICROALBUMINURIA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; PULSE WAVE; REVIEW; SODIUM INTAKE; ANIMAL; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANIMALS; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84903993734     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.04.006     Document Type: Review

References (167)

1. Rocha R., Stier C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
2. Hostetter T.H., Rosenberg M.E., Ibrahim H.N., Juknevicius I. Aldosterone in progressive renal disease. Semin Nephrol 2001, 21:573-579.
3. Hostetter T.H., Ibrahim H.N. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003, 14:2395-2401.
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
5. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
6. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2012, 2:337-414. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012.
7. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012.
8. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
9. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
10. de Zeeuw D., Remuzzi G., Parving H.-H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
11. Becker G.J., Hewitson T.D., Chrysostomou A. Aldosterone in clinical nephrology--old hormone, new questions. Nephrol Dial Transplant 2009, 24:2316-2321.
12. Young M., Fullerton M., Dilley R., Funder J.Mineralocorticoids hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
13. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
14. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
15. Greene E.L., Kren S., Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063-1068.
16. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
17. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
18. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A.G., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791-1800.
19. Grossmann C., Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53-62.
20. Sato A., Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004, 27:303-310.
21. Joffe H.V., Adler G.K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005, 10:31-37.
22. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232-237.
23. Nagase M., Matsui H., Shibata S., Gotoda T., Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877-883.
24. Mano A., Tatsumi T., Shiraishi J., et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 2004, 110:317-323.
25. Burniston J.G., Saini A., Tan L.-B., Goldspink D.F. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 2005, 39:395-399.
26. Pérez-Rojas J., Blanco J.A., Cruz C., et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007, 292:F131-F139.
27. Iwazu Y., Muto S., Fujisawa G., et al. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. Hypertension 2008, 51:749-754.
28. Brown N.J., Nakamura S., Ma L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58:1219-1227.
29. Nishiyama A., Yao L., Nagai Y., et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004, 43:841-848.
30. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
31. Nishiyama A., Yao L., Fan Y., et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005, 45:710-716.
32. Shibata S., Nagase M., Yoshida S., Kawachi H., Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
33. Quinkler M., Zehnder D., Eardley K.S., et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005, 112:1435-1443.
34. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006, 91:2214-2217.
35. Aldigier J.C., Kanjanbuch T., Ma L.-J., Brown N.J., Fogo A.B. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16:3306-3314.
36. Nemeth Z., Kokeny G., Godo M., et al. Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes. Nephrol Dial Transplant 2009, 24:3640-3651.
37. Fujisawa G., Okada K., Muto S., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66:1493-1502.
38. Toyonaga J., Tsuruya K., Ikeda H., et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011, 26:2475-2484.
39. Yuan J., Jia R., Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007, 8:118-126.
40. Banki N.F., Ver A., Wagner L.J., et al. Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats. PLoS One 2012, 7:e39938.
41. Han S.-Y., Kim C.-H., Kim H.-S., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362-1372.
42. Han K.H., Kang Y.S., Han S.-Y., et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006, 70:111-120.
43. Kang Y.S., Ko G.J., Lee M.H., et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009, 24:73-84.
44. Cha D.R., Kang Y.S., Han S.Y., et al. Role of aldosterone in diabetic nephropathy. Nephrology 2005, 10(Suppl):S37-S39.
45. Cooper J.N., Fried L., Tepper P., et al. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res 2013, 36:895-901.
46. de Paula R.B., da Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
47. Nagase M., Yoshida S., Shibata S., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006, 17:3438-3446.
48. Asai M., Monkawa T., Marumo T., et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 2004, 27:971-978.
49. Nakhoul F., Khankin E., Yaccob A., et al. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 2008, 294:F628-F637.
50. McCurley A., Pires P.W., Bender S.B., et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012, 18:1429-1433.
51. Lang F., Ritz E., Voelkl J., Alesutan I. Vascular calcification--is aldosterone a culprit?. Nephrol Dial Transplant 2013, 28:1080-1084.
52. Voelkl J., Alesutan I., Leibrock C.B., et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013, 123:812-822.
53. Gros R., Ding Q., Armstrong S., O'Neil C., Pickering J.G., Feldman R.D. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 2007, 292:C788-C794.
54. Arima S., Kohagura K., Xu H.-L., et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003, 14:2255-2263.
55. Bobadilla N.A., Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007, 293:F2-F9.
56. Feria I., Pichardo I., Juárez P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003, 63:43-52.
57. Pérez-Rojas J.M., Derive S., Blanco J.A., et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005, 289:F1020-F1030.
58. Ramírez V., Trujillo J., Valdes R., et al. Adrenalectomy prevents renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009, 297:F932-F942.
59. Mejía-Vilet J.M., Ramírez V., Cruz C., Uribe N., Gamba G., Bobadilla N.A. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007, 293:F78-F86.
60. Sánchez-Pozos K., Barrera-Chimal J., Garzón-Muvdi J., et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant 2012, 27:3160-3169.
61. Barrera-Chimal J., Pérez-Villalva R., Rodríguez-Romo R., et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 2013, 83:93-103.
62. Dworkin L.D., Benstein J.A., Tolbert E., Feiner H.D. Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J Am Soc Nephrol 1996, 7:437-442.
63. Wang Q., Clement S., Gabbiani G., et al. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 2004, 286:F1178-F1184.
64. Yu H.C., Burrell L.M., Black M.J., et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998, 98:2621-2628.
65. Hirawa N., Uehara Y., Kawabata Y., et al. High salt intake potentiates the renal vascular and glomerular damage caused by low doses of angiotensin II in uni-nephrectomized rats. J Hypertens 1999, 17:923-932.
66. Kawarazaki H., Ando K., Fujita M., et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 2011, 300:F1402-F1409.
67. Verhave J.C., Hillege H.L., Burgerhof J.G.M., et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004, 256:324-330.
68. Fox C.S., Larson M.G., Hwang S.-J., et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064-2069.
69. Cianciaruso B., Bellizzi V., Minutolo R., et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab 1998, 24:296-301.
70. Pimenta E., Gaddam K.K., Pratt-Ubunama M.N., et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008, 51:339-344.
71. Shibata S., Mu S., Kawarazaki H., et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011, 121:3233-3243.
72. Farjah M., Roxas B.P., Geenen D.L., Danziger R.S. Dietary salt regulates renal SGK1 abundance: relevance to salt sensitivity in the Dahl rat. Hypertension 2003, 41:874-878.
73. Nagase M., Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013, 9:86-98.
74. Shibata S., Nagase M., Yoshida S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370-1376.
75. Kawarazaki W., Nagase M., Yoshida S., et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012, 23:997-1007.
76. Berl T., Katz F.H., Henrich W.L., de Torrente A., Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978, 14:228-235.
77. Hené R.J., Boer P., Koomans H.A., Mees E.J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982, 21:98-101.
78. Reams G.P., Bauer J.H. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986, 146:2145-2148.
79. Bomback A.S., Klemmer P.J. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012, 33:119-124.
80. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24:789-796.
81. Bomback A.S., Klemmer P.J. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol 2009, 30:140-146.
82. Sarzani R., Guerra F., Mancinelli L., Buglioni A., Franchi E., Dessì-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens 2012, 25:818-826.
83. Bomback A.S., Kshirsagar A.V., Ferris M.E., Klemmer P.J. Disordered aldosterone-volume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009, 10:230-236.
84. Schrier R.W., Masoumi A., Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010, 5:1132-1140.
85. Hung S.-C., Lin Y.-P., Huang H.-L., Pu H.-F., Tarng D.-C. Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One 2013, 8:e57511.
86. Volk M.J., Bomback A.S., Klemmer P.J. Mineralocorticoid receptor blockade in chronic kidney disease. Curr Hypertens Rep 2011, 13:282-288.
87. Klemmer P.J., Bomback A.S. Extracellular volume and aldosterone interaction in chronic kidney disease. Blood Purif 2009, 27:92-98.
88. Ando K., Ohtsu H., Arakawa Y., et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010, 33:616-621.
89. Nagase M., Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res 2009, 32:649-657.
90. Vogt L., Waanders F., Boomsma F. de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19:999-1007.
91. Krikken J.A., Laverman G.D., Navis G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009, 18:531-538.
92. Naruse M., Tanabe A., Sato A., et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002, 40:28-33.
93. Bomback A.S., Rekhtman Y., Klemmer P.J., Canetta P.A., Radhakrishnan J., Appel G.B. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens 2012, 6:338-345.
94. Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
95. Horita Y., Taura K., Taguchi T., Furusu A., Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 2006, 11:462-466.
96. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-492.
97. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996, 2:47-54.
98. Lakkis J., Lu W.X., Weir M.R. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003, 5:408-417.
99. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936-1939.
100. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995, 9:145-149.
101. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
102. Beygui F., Montalescot G., Vicaut E., et al. Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en charge hospitalière, l[U+05F3]Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J 2009, 157:680-687.
103. Cicoira M., Zanolla L., Franceschini L., et al. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 89:403-407.
104. Shiigai T., Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477-483.
105. Ustundag A., Tugrul A., Ustundag S., Sut N., Demirkan B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail 2008, 30:982-991.
106. Bianchi S., Bigazzi R., Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005, 46:45-51.
107. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.
108. Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001, 29:13-21.
109. Bomback A.S., Muskala P., Bald E., Chwatko G., Nowicki M. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin Nephrol 2009, 72:449-456.
110. Moranne O., Bakris G., Fafin C., Favre G., Pradier C., Esnault VLM. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol 2013, 8:1694-1701.
111. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.
112. Chrysostomou A., Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001, 345:925-926.
113. Yonemura K., Yasuda H., Hishida A. Distinct responses of membranoproliferative glomerulonephritis-related proteinuria to spironolactone with and without angiotensin II blockade. Ann Intern Med 2003, 139:W79.
114. Kuriyama S., Sugano N., Ueda H., Otsuka Y., Kanzaki G., Hosoya T. Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease. Clin Exp Nephrol 2009, 13:663-666.
115. Kaito H., Nozu K., Iijima K., et al. The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 2006, 21:1824-1829.
116. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
117. Williams G.H., Burgess E., Kolloch R.E., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93:990-996.
118. Sato A., Hayashi K., Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44-49.
119. Apperloo A.J., de Zeeuw D., de Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997, 51:793-797.
120. Holtkamp F.A., de Zeeuw D., Thomas M.C., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011, 80:282-287.
121. Chrysostomou A., Pedagogos E., MacGregor L., Becker GJ. Double-blind placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
122. Edwards N.C., Steeds R.P., Chue C.D., Stewart P.M., Ferro C.J., Townend J.N. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012, 73:447-454.
123. Furumatsu Y., Nagasawa Y., Tomida K., et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008, 31:59-67.
124. Tylicki L., Rutkowski P., Renke M., et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008, 52:486-493.
125. Tsuboi N., Kawamura T., Okonogi H., Ishii T., Hosoya T. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 2012, 13:113-117.
126. Boesby L., Elung-Jensen T., Klausen T.W., Strandgaard S., Kamper A.-L. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 2011, 6:e26904.
127. Morales E., Millet V.G., Rojas-Rivera J., et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013, 28:405-412.
128. Sengul E., Sahin T., Sevin E., Yilmaz A. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. Ren Fail 2009, 31:928-932.
129. Ogawa S., Takeuchi K., Mori T., Nako K., Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006, 33:477-479.
130. van den Meiracker A.H., Baggen R.G., Pauli S., et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006, 24:2285-2292.
131. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., Parving H.-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106-2112.
132. Davidson M.B., Wong A., Hamrahian A.H., Stevens M., Siraj E.S. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract 2008, 14:985-992.
133. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006, 70:536-542.
134. Saklayen M.G., Gyebi L.K., Tasosa J., Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Invest Med 2008, 56:714-719.
135. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836.
136. Nielsen S.E., Persson F., Frandsen E., et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012, 29:e184-e190.
137. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
138. Esteghamati A., Noshad S., Jarrah S., Mousavizadeh M., Khoee S.H., Nakhjavani M. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transplant 2013, 28:2823-2833.
139. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
140. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30:418-424.
141. Pisoni R., Acelajado M.C., Cartmill F.R., et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Human Hypertens 2012, 26:502-506.
142. Abolghasmi R., Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011, 22:75-78.
143. Gross E., Rothstein M., Dombek S., Juknis H.I. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005, 46:94-101.
144. Shavit L., Neykin D., Lifschitz M., Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Clin Nephrol 2011, 76:388-395.
145. Vardeny O., Wu D.H., Desai A., et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012, 60:2082-2089.
146. Edwards N.C., Steeds R.P., Stewart P.M., Ferro C.J., Townend J.N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505-512.
147. Sato A., Funder J.W., Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999, 12:867-873.
148. Steigerwalt S., Zafar A., Mesiha N., Gardin J., Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007, 27:159-163.
149. Taheri S., Mortazavi M., Shahidi S., et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009, 20:392-397.
150. Taheri S., Mortazavi M., Pourmoghadas A., Seyrafian S., Alipour Z., Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012, 23:507-512.
151. Fukuta H., Hayano J., Ishihara S., et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 2003, 18:318-325.
152. Flevari P., Kalogeropoulou S., Drakou A., et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 2013, 31:1239-1244.
153. Nitta K., Akiba T., Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003, 115:250.
154. Vukusich A., Kunstmann S., Varela C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:1380-1387.
155. Navaneethan S.D., Nigwekar S.U., Sehgal A.R., Strippoli G.F.M. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009, 3. (CD007004).
156. Roscioni S.S., de Zeeuw D., Bakker SJL, Lambers Heerspink H.J. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012, 8:691-699.
157. Chua D., Lo A., Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?. Clin Cardiol 2010, 33:604-608.
158. Baker W.L., White W.B. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012, 46:889-894.
159. Rekhtman Y. Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease. Curr Hypertens Rev 2012, 8:267-275.
160. Hausmann M.J., Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002, 17:2035-2036.
161. Butler J.V., McAvoy H., McEnroy D., Mulkerrin E.C. Spironolactone therapy in older patients--the impact of renal dysfunction. Arch Gerontol Geriatr 2002, 35:45-49.
162. Erden I., Yalcin S., Ozhan H. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone. Kardiol Pol 2010, 68:1043-1045. discussion 6.
163. Schepkens H., Vanholder R., Billiouw J.M., Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110:438-441.
164. Momeni A, Behradmanesh MS, Kheiri S, Horestani MK. Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. J Renin Angiotensin Aldosterone Syst. 2013. Epub ahead of print.
165. Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. ONTARGET Investigators.
166. Mann J.F.E., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
167. Bomback A.S., Kshirsagar A.V., Klemmer P.J. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?. Nat Clin Pract Nephrol 2009, 5:74-75.